Loading profile…
Pulling IRS BMF, Form 990 filings, peer benchmarks, programs, people, and grants.
Pulling IRS BMF, Form 990 filings, peer benchmarks, programs, people, and grants.
DBA: N/A
EIN 47-2589708 · Snapshot of IRS recognition, filing currency, financial health, and governance.
Accelerating the development of advanced diagnostic tools and effective treatments for systemic Amyloidosis through collaboration and innovation.
Principal Officer
Isabelle Lousada
Total Revenue
$3.4M
FY2024
Total Expenses
$3.0M
FY2024
Net Assets
$3.1M
Program Ratio
78.0%
expenses on programs
Employees
20
Volunteers
0
Board Members
8
Voting
7
Independent
8 answers compiled from IRS Form 990, BMF, Pub 78, and the Auto-Revocation List.